Pharmacokinetics, Safety, and Tolerability of Once‐Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed‐Dose Combination

By  

Clinical Pharmacology In Drug Development, Vol. 5, Iss. 3, 2016-05 ,pp. : 225-231

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies

By Marcellin Patrick   Roberts Stuart K   Reddy K Rajender   Harrison Stephen A   Jensen Donald M   Hadziyannis Stephanos   Diago Moises   Weltman Martin   Messinger Diethelm   Tatsch Fernando   Rizzetto Mario  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 901-909

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Efficacy and Safety of Efavirenz Dose Reduction to 200 mg Once Daily in a Caucasian Patient with HIV

By >   Gómez Alicia Iglesias  

Clinical Drug Investigation, Vol. 30, Iss. 6, 2010-06 ,pp. : 405-411

Adis International

Access to resources Recommend Favorite

Conversion from Standard Opioid Therapy to Once-daily Oral Extended-release Hydromorphone in Patients with Chronic Cancer Pain

By Wallace M   Rauck RL   Moulin D   Thipphawong J   Khanna S   Tudor IC  

The Journal of International Medical Research, Vol. 36, Iss. 2, 2008-03 ,pp. : 343-352

Field House Publishing

Access to resources Recommend Favorite

Pharmacokinetic profile of once-daily cyclobenzaprine extended-release

By Darwish Mona   Hellriegel Edward T  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 6, Iss. 11, 2010-11 ,pp. : 1425-1436

Informa Healthcare

Access to resources Recommend Favorite